BioCentury | Jul 29, 2013
Clinical News

HT-100: Phase Ib/IIa started

...Dart's Halo Therapeutics LLC subsidiary began an open-label, U.S. Phase Ib/IIa evaluating single and multiple ascending-doses of HT-100...
BioCentury | Jun 3, 2013
Product Development

The DMD landscape

...to have improved GI tolerability over halofuginone. According to Williams, HT-100 was originally developed by Halo Therapeutics LLC...
BioCentury | Mar 11, 2013
Product Development

Neomics' new tricks

...approach, aTyr's platform focuses on secreted forms of ARS (see BioCentury, Aug. 9, 2010 ). Halo Therapeutics LLC...
...Diego, Calif. Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Lexington, Mass. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Halo Therapeutics LLC...
BioCentury | May 28, 2012
Company News

Halo Therapeutics musculoskeletal news

...the indication, from Collgard Biopharmaceuticals Ltd. (Petah Tikva, Israel) last year (see BioCentury, Jan. 9). Halo Therapeutics LLC...
BioCentury | May 14, 2012
Clinical News

Halofuginone regulatory update

...the U.S., from Collgard Biopharmaceuticals Ltd. (Petah Tikva, Israel) last year (see BioCentury, Jan. 9). Halo Therapeutics LLC...
BioCentury | Mar 15, 2012
Targets & Mechanisms

Halofuginone target ID

...least one company has a halofuginone analog about to enter the clinic. By year end, Halo Therapeutics LLC...
...Institutions Mentioned Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Ewha Womans University , Seoul, South Korea Halo Therapeutics LLC...
BioCentury | Mar 8, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

...Ongoing work includes synthesizing halofuginone analogs and looking for druggable downstream targets in the pathway. Halo Therapeutics LLC...
BioCentury | Mar 8, 2012
Distillery Therapeutics

Indication: Autoimmune Disease

...Ongoing work includes synthesizing halofuginone analogs and looking for druggable downstream targets in the pathway. Halo Therapeutics LLC...
BioCentury | Feb 13, 2012
Emerging Company Profile

Halo: Treating DMD symptoms

...developing therapeutics for Duchenne muscular dystrophy are targeting the genetic defects that cause the disease. Halo Therapeutics LLC...
...Inc. , Cambridge, Mass. Charley's Fund , Stockbridge, Mass. Collgard Biopharmaceuticals Inc. , Petah-Tikva, Israel Halo Therapeutics LLC...
...Minneapolis, Minn. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland University of Manitoba , Winnipeg, Manitoba Sidebars Halo Therapeutics LLC...
BioCentury | Jan 9, 2012
Clinical News

Halofuginone regulatory update

...this year. Halo acquired the product from Collgard Biopharmaceuticals Ltd. (Petah Tikva, Israel) last year. Halo Therapeutics LLC...
Items per page:
1 - 10 of 11
BioCentury | Jul 29, 2013
Clinical News

HT-100: Phase Ib/IIa started

...Dart's Halo Therapeutics LLC subsidiary began an open-label, U.S. Phase Ib/IIa evaluating single and multiple ascending-doses of HT-100...
BioCentury | Jun 3, 2013
Product Development

The DMD landscape

...to have improved GI tolerability over halofuginone. According to Williams, HT-100 was originally developed by Halo Therapeutics LLC...
BioCentury | Mar 11, 2013
Product Development

Neomics' new tricks

...approach, aTyr's platform focuses on secreted forms of ARS (see BioCentury, Aug. 9, 2010 ). Halo Therapeutics LLC...
...Diego, Calif. Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Lexington, Mass. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Halo Therapeutics LLC...
BioCentury | May 28, 2012
Company News

Halo Therapeutics musculoskeletal news

...the indication, from Collgard Biopharmaceuticals Ltd. (Petah Tikva, Israel) last year (see BioCentury, Jan. 9). Halo Therapeutics LLC...
BioCentury | May 14, 2012
Clinical News

Halofuginone regulatory update

...the U.S., from Collgard Biopharmaceuticals Ltd. (Petah Tikva, Israel) last year (see BioCentury, Jan. 9). Halo Therapeutics LLC...
BioCentury | Mar 15, 2012
Targets & Mechanisms

Halofuginone target ID

...least one company has a halofuginone analog about to enter the clinic. By year end, Halo Therapeutics LLC...
...Institutions Mentioned Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Ewha Womans University , Seoul, South Korea Halo Therapeutics LLC...
BioCentury | Mar 8, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

...Ongoing work includes synthesizing halofuginone analogs and looking for druggable downstream targets in the pathway. Halo Therapeutics LLC...
BioCentury | Mar 8, 2012
Distillery Therapeutics

Indication: Autoimmune Disease

...Ongoing work includes synthesizing halofuginone analogs and looking for druggable downstream targets in the pathway. Halo Therapeutics LLC...
BioCentury | Feb 13, 2012
Emerging Company Profile

Halo: Treating DMD symptoms

...developing therapeutics for Duchenne muscular dystrophy are targeting the genetic defects that cause the disease. Halo Therapeutics LLC...
...Inc. , Cambridge, Mass. Charley's Fund , Stockbridge, Mass. Collgard Biopharmaceuticals Inc. , Petah-Tikva, Israel Halo Therapeutics LLC...
...Minneapolis, Minn. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland University of Manitoba , Winnipeg, Manitoba Sidebars Halo Therapeutics LLC...
BioCentury | Jan 9, 2012
Clinical News

Halofuginone regulatory update

...this year. Halo acquired the product from Collgard Biopharmaceuticals Ltd. (Petah Tikva, Israel) last year. Halo Therapeutics LLC...
Items per page:
1 - 10 of 11